Back to search

Article

A Novel Cell-Free DNA Fragmentomics Assay and Its Application for Monitoring Disease Progression in Real-Time for Stage IV Cancer Patients

2025-08-13

Abstract excerpt

<h4>Background: </h4> /Objectives: Conventional imaging assesses therapy response in stage IV solid-tumor patients in 8–12-week intervals, delaying detection of non-responders. We evaluated a real-time quantitative PCR (RT-qPCR) assay that interrogates size-distributed cell-free DNA (cfDNA) fragments to provide earlier insights into treatment efficacy. <h4>Methods:</h4> In this prospective study, 128 patients with...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7ed1ec4d-2a32-5831-9081-398dec417509
DOI
10.20944/preprints202508.0913.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A Novel Cell-Free DNA Fragmentomics Assay and Its Application for Monitoring Disease Progression in Real-Time for Stage IV Cancer PatientsDOI 10.20944/preprints202508.0913.v1
Cancer treatment monitoring using cell-free DNA fragmentomes.Semantic proximity
Cell-Free DNA Concentration as a Mutation-Agnostic Readout of Systemic Tumor Burden and Prognosis: A Prospective Analysis of 1,000 PatientsSemantic proximity
Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challengesSemantic proximity
Combining tumor genomic and transcriptomic analysis with liquid biopsy ctDNA monitoring: analytical validation and clinical insightsSemantic proximity
Low-coverage whole-genome sequencing of plasma cell-free DNA to predict treatment response and progression-free survival in advanced NSCLC receiving EGFR-tyrosine kinase inhibitors or chemotherapy: A pilot prospective studySemantic proximity
Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer StudySemantic proximity
Early Assessment of Molecular Progression and Response by Whole-genome Circulating Tumor DNA in Advanced Solid Tumors.Semantic proximity
Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers.Semantic proximity
Computational Modeling for Circulating Cell-Free DNA in Clinical Oncology.Semantic proximity
Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors.Semantic proximity
Cell-free DNA fragmentomics: a universal framework for early cancer detection and monitoringSemantic proximity
Longitudinal cell-free DNA characterization by low-coverage whole-genome sequencing in patients undergoing high-dose radiotherapySemantic proximity
Select a neighboring publication to make it the new centre.